Aripiprazole Combination Composition for KRAS G12C Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for KRAS G12C genetic mutations, such as sotorasib and adagrasib, have limited efficacy in inducing apoptosis in cancer cells, particularly in treating KRAS G12C-mutated non-small cell lung cancer with brain metastasis, and there is a need for enhanced anticancer effects.
Innovation Solution
A pharmaceutical and health functional food composition incorporating aripiprazole as an active ingredient, which enhances the anticancer effect of therapeutic agents for KRAS G12C genetic mutations by inducing apoptosis through increased expression of NOXA protein and PARP cleavage when co-administered with these agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents for KRAS G12C genetic mutation (such as sotorasib and adagrasib) are used alone, then the anticancer effect is limited, but adding combination therapies increases treatment complexity and potential side effects
Solution Approach 1:
The patent introduces an intermediary substance (ahrefine or aripiprazole) that mediates between the KRAS G12C therapeutic agent and cancer cells. This intermediary enhances the apoptotic effect by modulating BH3-only protein expression and PARP cleavage, thereby amplifying the anticancer effect without requiring complex multi-drug regimens. The intermediary acts as a bridge that strengthens the therapeutic agent's ability to induce apoptosis while maintaining treatment simplicity.
2Reliability
If BH3 mimetics or BH3-only protein-inducing drugs are used to enhance apoptosis, then the apoptotic effect is potentiated, but the risk of inducing harmful effects increases
Solution Approach 1:
The patent applies parameter changes by modulating the expression levels of BH3-only proteins (such as NOXA) and the extent of PARP cleavage. By carefully controlling these parameters through the intermediary substance, the patent achieves potent apoptosis induction while preventing excessive or harmful effects. The parameter modulation allows for a balanced apoptotic response that targets cancer cells effectively without causing undue harm to healthy tissues.
Data Source
AI summary
The present invention relates to a composition containing aripiprazole as an active ingredient for enhancing the anti-cancer effect of a KRAS G12C genetic mutation therapeutic agent. More specifically, the present invention concerns a composition for enhancing the anticancer effect of a KRAS G12C genetic mutation therapeutic agent, which acts as an enhancer for the anti-cancer effect of the KRAS G12C genetic mutation therapeutic agent when used in combination therapy with aripiprazole, thereby enabling the treatment of cancer. When used at an effective dose in combination with a KRAS G12C genetic mutation therapeutic agent, aripiprazole according to the present invention excellently enhances the anticancer effect of the KRAS G12C genetic mutation therapeutic agent by inducing cancer cell death, etc. Thus, it can be advantageously used as an enhancer for the anti-cancer effect of the KRAS G12C genetic mutation therapeutic agent.